Why the study?
Does transcatheter aortic valve implantation with the Evolut platform provide favorable valve performance and clinical outcomes in patients with bicuspid aortic stenosis?
Does transcatheter aortic valve implantation with the Evolut platform provide favorable valve performance and clinical outcomes in patients with bicuspid aortic stenosis?
TAVI with the Evolut platform appears to offer favorable valve performance and clinical outcomes for treating bicuspid aortic stenosis, independent of the sizing methodology used.
Answers are grounded in this paper and cite their sources.
Supports Evolut TAVI in bicuspid AS; leaves open sizing methodology effects pending prospective data.
BIVOLUTX demonstrated a favourable bioprosthetic valve performance and good clinical outcomes after TAVI with the Evolut platform in patients with bicuspid aortic stenosis. No impact from the sizing methodology could be identified.
No takes yet. Share an insight, caveat, or question.
Tchétché et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: